Navigation Links
Ventana paves the way for companion diagnostic early phase clinical trials in China to advance patient care
Date:8/5/2014

TUCSON, Ariz., Aug. 5, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announces a new agreement with Quintiles, Inc. to offer College of American Pathology (CAP)-standard companion diagnostic testing services in China for pharmaceutical and biotech companies conducting early phase clinical trials. This is great news for patients as China is one of the only countries in the world that requires all patient samples be tested in China, even those used in clinical trials.

"Our new relationship with Quintiles to offer companion diagnostic testing services in China moves our mission, to improve the lives of all patients afflicted with cancer, a big step forward," said Doug Ward, VP and Companion Diagnostics Lifecycle Leader. "Our oncology pharma collaborators can now reach a large and growing number of patients that can benefit from clinical trial participation using targeted treatments and tests."

According to the World Health Organization (WHO)'s latest World Cancer Report, China had the highest rate of new cancer cases recorded globally in 2012 with 21.9%, or 3.07 million, and the trend is increasing, particularly in lung, liver, esophageal and stomach cancers1.  This underscores the growing need for patients in China to have in-country access to the most advanced tissue diagnostic testing and companion therapeutics in the industry, which starts with early phase clinical trials.

"It's been extremely important to Ventana that we find a strategic laboratory in China that will help us uphold the CAP testing standard of excellence set by our global companion diagnostic CAP/CLIA laboratory in Tucson, Arizona, USA," said Dr. H. James Hnatyszyn, Director Laboratory Operations for VENTANA companion diagnostic services. "Quintiles has the experience, infrastructure and qualified personnel to meet this challenge."

Early phase clinical trial testing according to the rigorous CAP standards set by Ventana is available now.

About Companion Diagnostics

Companion diagnostics are tests designed to confirm the presence of a specific biomarker and assist physicians in selecting effective therapies for their patients. For pharmaceuticals, incorporating a companion diagnostic strategy into a drug development program may expedite the approval process and help generate more effective drugs with improved safety profiles for patients.

1World Health Organization, World Cancer Report, 2014, Edited by Bernard W. Stewart and Christopher P. Wild

About Ventana Medical Systems, Inc.
Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA products are used in clinical histology and drug development research laboratories worldwide. The company's intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to help reduce errors, support diagnosis and enable informed treatment decisions by anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies. VENTANA and the VENTANA logo are trademarks of Roche.

VMSI Media Relations
Jacqueline Bucher
Senior Director, Corporate Communications
Phone: 520-877-7288
e-mail: Jacquie Bucher

Photo - http://photos.prnewswire.com/prnh/20140801/132766


'/>"/>
SOURCE Ventana Medical Systems, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
2. Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer patients
3. Ventana Supports World Patient Safety Day, July 25
4. Ventana Medical Systems, Inc. develops first-ever fully automated dual-stain technique for miRNA and protein detection in cancer
5. MedeAnalytics Receives Leadership Award from Ventana Research
6. Ventana and Biocare Medical sign p63 license agreement to aid in the differential diagnosis of benign and malignant prostate lesions
7. Ventana and Barco revolutionize digital pathology viewing experience
8. Ventana and EMC join forces to take digital pathology into the world of Big Data
9. Ventana receives approval from Chinas FDA for first fully automated IHC companion diagnostic identifying ALK protein expression in lung cancer patients
10. Ventana launches fully automated Gram Stain on the BenchMark Special Stains platform
11. Ventana to partner with Incyte on the development of Companion Diagnostic tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
Breaking Medicine Technology:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
Breaking Medicine News(10 mins):